P57 (KIP2) polymorphisms and breast cancer risk

Human Genetics

Volumn 104, Issue 1, 1999, Pages 83-88

  Li, Yu ^a   Millikan, Robert C ^a   Newman, Beth ^a   Conway, Kathleen ^a   Tse, Chiu Kit J ^a   Liu, Edison T ^b  

^a IL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CHROMOSOME 11P; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE DELETION; HUMAN; MAJOR CLINICAL STUDY; NEGRO; NORMAL HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P57; FEMALE; HUMANS; MIDDLE AGED; NORTH CAROLINA; NUCLEAR PROTEINS; ODDS RATIO; POLYMORPHISM, GENETIC; REPETITIVE SEQUENCES, NUCLEIC ACID; RISK FACTORS; SEQUENCE DELETION;

EID: 0033016884     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004390050914     Document Type: Article

References (25)

1. Aldrich T. Vann D, Moorman P, Newman B (1995) Rapid reporting of cancer incidence in a population-based study of breast cancer: constructive use of a central cancer registry. Breast Cancer Res Treat 35:61-64
2. Breslow N, Day N (1980) Statistical methods in cancer research: the analysis of case-control studies. International Agency for Research on Cancer, Lyon
3. Cavalli-Sforza L, Bodmer W (1971) The genetics of human populations. Freeman, San Francisco
4. Hashimoto Y, Kohri K, Kaneko Y, Morisaki H, Kato T, Ikeda K, Nakanishi M (1998) Critical role for the 310 helix region of p57 (Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression. J Biol Chem 273:16544-16550
5. Hatada I, Inazawa J, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi H, Fukushima Y, Iida K, Yatani C, Takashashi S, Chiba Y, Ohishi S, Muaki T (1996a) Genomic imprinting of human P57-KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet 5:783-788
6. Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, Jakayama M, Niikawa N, Mukai T (1996b) An imprinted gene P57-KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 14:171-178
7. Kondo M, Matsuoka S, Uchida K, Osada H, Nagatake M, Takagi K, Harper J, Toshitada T, Elledge S, Takahashi T (1996) Selective maternal-allele loss in human lung cancers of the maternally expressed P57-KIP2 gene at 11p15.5. Oncogene 12:1365-1368
8. Laken S, Petersen G, Gruber S, Oddoux C, Ostrer H, Giardiello F, Hamilton S, Hampel H, Markowitz A, Klimstra D, Jhanwar S, Winawer S, Offit K, Luce M, Kinzler K, Vogelstein B (1997) Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17:79-83
9. Lee M, Reynisdottir I, Massague J (1995) Cloning of P57-KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649
10. Lee M, DeBaun M, Randhawa G, Reichard B, Elledge S, Feinberg A (1997) Low frequency of P57-KIP2 mutation in Beckwith-Weidemann syndrome. Am J Hum Genet 61:304-309
11. Matsuoka S, Edwards M, Bai C, Parker S, Zhang P, Bladini A, Harper J, Elledge S (1995) p57-KIP2, a structurally different member of the p21-CIP 1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662
12. Matsuoka S, Thompson J, Edwards M, Batletta J, Grundy P, Kalikin L, Harper J, Elledge S, Feinberg A (1996) Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor,P57-KIP2, on chromosome 11p15. Proc Natl Acad Sci USA 93:3026-3030
13. Millikan R, Pittman G, Newman B, Tse C-K, Selmin O, Rockhill B, Savitz D, Moorman P, Bell D (1998) Cigarette smoking. N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7:371-378
14. Newman B, Moorman P, Millikan R, Qaqish B, Geradts J, Aldrich T, Liu E (1995) The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 34:51-60
15. O'Keefe D, Dao D, Zhao L, Sanderson R, Warburton D, Weiss L, Anyane-Yeboa K, Tycko B (1997) Coding mutations in P57-KIP2 are present in some cases of Beckwith-Weidemann syndrome but are rare or absent in Wilms' Tumors. Am J Hum Genet 61:295-303
16. Orlow O, Weissman B, Cordon C (1996) Cyclin-dependent kinase inhibitor p57-KIP2 in soft tissue sarcomas and Wilms' tumors. Cancer Research 56:1219-1221
17. Reid L, Crider-Miller S, West A, Lee M-H, Massague J, Weissman B (1996) Genomic organization of the human P57-KIP2 gene and its analysis in the G401 Wilms' tumor assay. Cancer Res 56:1214-1218
18. Rosner B (1990) Fundamentals of biostatistics. PWS-Kent, Boston
19. Sambrook H, Maniatis T, Fritsch F (1988) Molecular cloning: a laboratory manual. 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
20. Schlesselman J (1982) Case-control studies: design, conduct, analysis. Oxford University Press, New York
21. Seizinger B, Deimling A (1991) Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 58:1080-1096
22. Tokino T, Urano T, Furuhata T, Matsushima M, Miyatsu T, Sasaki S, Nakamura Y (1996) Characterization of the human P57 gene: alternative splicing insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet 97:625-631
23. Weinberg C, Sandler D (1991) Randomized recruitment in case-control studies. Am J Epidemiol 134:421-432
24. Woodage T, King S, Wacholder S, Hartge P, Struewing J, McAdams M, Laken S, Tucker M, Brody L (1998) The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 20:62-65
25. Zhang P, Liegeois N, Wong C, Finegold M, Hou H, Thompson J, Silverman A, Harper J, DePinho R, Elledge S (1997) Altered cell differentiation and proliferation in mice lacking P57-KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387:151-163